TrialRMD open2024

The effect of rituximab on patient reported outcomes in the preclinical phase of rheumatoid arthritis: 2 year data from the PRAIRI study.

Giulia Frazzei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.